• Masanori Harada, Keisuke Morikawa, Namio Kagoo, Yutaro Ito, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Kazuyo Yasuda, Masaru Tsukui, and Naoki Koshimizu.
• Department of respiratory medicine.
• Medicine (Baltimore). 2021 May 28; 100 (21): e26149e26149.

RationaleLung pleomorphic carcinoma (LPC) is generally resistant to chemotherapy or radiotherapy. However, a combination of immune checkpoint inhibitors and radiotherapy has a remarkable efficacy against LPC.Patient Concerns And DiagnosesHere, we report the case of a 50-year old man diagnosed with progressive LPC. The tumor invaded the carina and predominantly obstructed the right main bronchus; therefore, a combination of palliative chemoradiotherapy and atezolizumab was initiated. However the trachea was gradually obstructed.Intervention And OutcomeArgon plasma coagulation (APC) was performed to prevent tumor invasion. After three APC sessions, the tumor showed a necrotic change and was easily excised using biopsy forceps.LessonsA combination of chemoradiotherapy, atezolizumab, and APC showed a good efficacy, and the patient had a good response to atezolizumab maintenance therapy. Multidisciplinary treatments, such as a combination of immune checkpoint inhibitors and APC, could have synergistic efficacy in lung cancer.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…